Cutaneous Lymphoma in Dogs: Welfare Management

Cutaneous lymphoma is a rare but challenging dermatological cancer in dogs, with welfare management centred on skin comfort and quality of life throughout treatment.

Key Facts

Cutaneous lymphoma includes epitheliotropic T-cell lymphoma (CTCL/mycosis fungoides) and non-epitheliotropic B-cell or T-cell forms
CTCL progresses through erythema and scaling to plaque formation and ulceration over months to years
Pruritus (itching) is a significant welfare symptom in many cases, causing chronic distress and self-trauma from scratching
Retinoids (isotretinoin, etretinate) and chemotherapy protocols can provide palliation — complete remission is rare

Welfare Considerations

Cutaneous lymphoma welfare management requires sustained attention to skin comfort and pruritus control throughout a disease course that may extend over years. The chronic itch-scratch cycle causes persistent welfare impairment that is often undertreated. Retinoid therapy can substantially reduce scaling and pruritus in epitheliotropic forms, improving quality of life without curing the disease. Regular reassessment of welfare quality using validated canine scales enables timely treatment adjustments and honest prognosis discussions as the disease progresses.

What You Can Do

Prioritise pruritus control as a welfare imperative — uncontrolled itching significantly impairs quality of life
Discuss retinoid therapy with a dermatologist or oncologist — this can provide significant welfare improvement in epitheliotropic forms
Manage secondary skin infections promptly as these compound the primary disease welfare burden
Reassess quality of life regularly and establish advance directives for euthanasia triggers with your veterinarian